Antibody responses and reactogenicity of graded doses of inactivated influenza A/New Jersey/76 whole-virus vaccine in humans.
Graded doses of inactivated whole influenza A/New Jersey/8/76 virus vaccine were injected into healthy volunteers. Presence of hemagglutination-inhibiting (HAI) antibody was uncommon before vaccination in persons younger than 45 years and most common in those older than 65 years. All vaccine doses (4-61 microgram of hemagglutinin) induced HAI antibody in at least 50% of recipients, although a booster dose was required to induce high titers in those younger than 24 years of age. A tendency for HAI titers to increase with increasing age and dose was noted. A trivalent vaccine (composed of A/New Jersey/76, A/Victoria/75, and B/Hong Kong/73) given to persons 21-44 years old produced HAI antibody titers to A/New Jersey/76 similar to those produced by the same dose of A/New Jersey/76 as a monovalent vaccine and produced higher titers in subjects 65 years of age or older. Increases in neuraminidase-inhibiting antibody were small and infrequent. Local and system symptoms were commonly reported after vaccination but were mostly mild (11% had moderate pain and 19% had muscular aches). Reactions were less common among those with HAI antibody at the time of vaccination and were unacceptably severe (in 20% of recipients) only in seronegative recipients given the 61-microgram dose of hemagglutinin.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000375:Aging; D000914:Antibodies, Viral / Q000096:biosynthesis*; D002986:Clinical Trials as Topic; D004306:Dose-Response Relationship, Immunologic; D004311:Double-Blind Method; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D009980:Influenza A virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000494:pharmacology*; D008875:Middle Aged; D009439:Neuraminidase / Q000494:pharmacology; D013997:Time Factors
D000914:Antibodies, Viral; D007252:Influenza Vaccines; D009439:Neuraminidase